Immunocore Holdings plc (IMCR) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Immunocore Holdings plc (IMCR) Healthcare & Pipeline Overview

Immunocore Holdings plc is a UK-based commercial-stage biotechnology firm specializing in T-cell receptor (TCR) immunotherapies for oncology, infectious, and autoimmune diseases. Its lead product, KIMMTRAK, addresses unresectable or metastatic uveal melanoma, positioning the company in the precision medicine segment of the global biopharmaceutical market.

What Is the Investment Thesis for IMCR?

Immunocore Holdings plc presents an investment thesis centered on its proprietary T-cell receptor (TCR) immunotherapy platform and the commercialization of KIMMTRAK. The company's lead product, KIMMTRAK, for unresectable or metastatic uveal melanoma, generated $0.06B in Free Cash Flow, demonstrating initial commercial viability. This commercial success provides a foundation for funding its extensive pipeline. Key growth catalysts include the potential expansion of KIMMTRAK's indications or geographic reach, as well as the advancement of its oncology pipeline candidates, IMC-C103C and IMC-F106C, through later-stage clinical trials. Successful progression of these assets, particularly in large indications like NSCLC, could significantly increase the company's market opportunity. Furthermore, the diversification into infectious diseases (e.g., chronic hepatitis B with IMC-I109V) and autoimmune diseases offers long-term growth avenues beyond oncology. The company's high gross margin of 98.8% suggests strong pricing power and cost efficiency for its commercial product. However, risks include the inherent uncertainties of clinical development, potential competition from other immunotherapy platforms, and the negative profit margin of -4.9%, indicating ongoing R&D expenses and commercialization costs. The P/E ratio of -41.53 reflects current unprofitability, typical for a commercial-stage biotech heavily investing in its pipeline.

Based on FMP financials and quantitative analysis

IMCR Key Highlights

• Commercial-stage biotechnology company with an approved product, KIMMTRAK, for unresectable or metastatic uveal melanoma.
• Achieved a robust gross margin of 98.8%, indicating strong product profitability at the operational level.
• Reported a Free Cash Flow (FCF) of $0.06B, demonstrating positive cash generation from operations.
• Maintains a diversified pipeline with oncology programs (IMC-C103C, IMC-F106C) in Phase I/II trials and infectious disease candidates (IMC-I109V) also in Phase I/II.
• Operates with a market capitalization of $1.73B, positioning it as a mid-cap biotechnology firm.

Who Are IMCR's Competitors?

IMCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMCR's Key Strengths?

• Commercial-stage company with an approved, first-in-class product (KIMMTRAK) for a rare cancer.
• Proprietary ImmTAC® platform offers a unique mechanism to target intracellular antigens.
• Diversified pipeline across oncology, infectious, and autoimmune diseases.
• High gross margin of 98.8% for its commercial product.

What Are IMCR's Weaknesses?

• Negative profit margin (-4.9%) and P/E ratio (-41.53) indicate current unprofitability.
• Reliance on a single commercial product (KIMMTRAK) for current revenue generation.
• Significant ongoing R&D expenses inherent in biotechnology drug development.
• Relatively small employee base (493) compared to larger pharmaceutical competitors.

What Could Drive IMCR Stock Higher?

• Potential data readouts from Phase I/II trials for oncology candidates IMC-C103C and IMC-F106C, which could significantly de-risk these programs and attract further investor interest.
• Advancement of the chronic hepatitis B virus program, IMC-I109V, through its Phase I/II clinical trial, potentially demonstrating early efficacy or safety milestones.
• Continued commercial uptake and revenue growth of KIMMTRAK for uveal melanoma, driven by market penetration and potential geographic expansion.
• Initiation of new clinical trials for pipeline candidates or expansion into new therapeutic areas, such as autoimmune diseases, signaling pipeline progression and diversification.

What Are the Key Risks for IMCR?

• Financial-distress signal — its Altman Z-Score of 1.32 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-4.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected safety issues for any of its pipeline candidates (IMC-C103C, IMC-F106C, IMC-I109V), leading to delays or termination of development programs.
• Intense competition in the immunotherapy market from established pharmaceutical companies and other biotechnology firms developing similar or superior treatments.
• Regulatory hurdles and delays in obtaining approvals for new indications or pipeline products, which can significantly impact commercialization timelines and costs.
• Market access and reimbursement challenges for KIMMTRAK or future products, particularly in new geographic regions or for new indications, affecting profitability.
• Dependence on the commercial success of KIMMTRAK, with any decline in sales or market share negatively impacting the company's financial performance.

What Are the Growth Opportunities for IMCR?

• **Expansion of KIMMTRAK Indications:** Immunocore's lead product, KIMMTRAK, currently approved for unresectable or metastatic uveal melanoma, holds potential for label expansion into other melanoma subtypes or solid tumors where its mechanism of action could be beneficial. The global melanoma treatment market is projected to reach significant values, and even a small share of additional indications could substantially boost revenue. Further clinical trials exploring KIMMTRAK in combination therapies or earlier lines of treatment could unlock new patient populations and extend its market lifecycle, potentially within the next 3-5 years, leveraging existing regulatory pathways and commercial infrastructure.
• **Advancement of Oncology Pipeline (IMC-C103C and IMC-F106C):** The company's oncology pipeline, including IMC-C103C and IMC-F106C, both in Phase I/II dose escalation trials for various solid tumors like NSCLC, gastric, and breast cancers, represents substantial growth opportunities. The global market for NSCLC alone is projected to be in the tens of billions of dollars annually. Successful progression of these candidates through pivotal trials and subsequent regulatory approval could lead to blockbuster potential. These programs are targeting large patient populations with significant unmet needs, with potential commercialization timelines extending 5-10 years, contingent on clinical success and regulatory clearance.
• **Development in Infectious Diseases (IMC-I109V and IMC-M113V):** Immunocore's foray into infectious diseases, with IMC-I109V for chronic hepatitis B virus (HBV) in Phase I/II and IMC-M113V for human immunosuppression virus (HIV) in preclinical development, offers diversification and access to large global markets. The chronic HBV market is substantial, with millions of affected individuals worldwide, and effective curative therapies are highly sought after. Successful development in these areas could tap into markets worth billions annually. These programs represent longer-term growth drivers, with potential commercialization beyond 7-10 years, offering significant future revenue streams.
• **Entry into Autoimmune Diseases:** The company is developing product candidates for precision-targeted immunosuppression in autoimmune diseases. The global autoimmune disease market is vast and growing, encompassing conditions like rheumatoid arthritis, lupus, and multiple sclerosis, with market sizes often reaching tens of billions of dollars. Leveraging its TCR platform to specifically target disease-driving cells or pathways in autoimmune conditions could create a highly differentiated therapeutic approach. This represents a strategic diversification opportunity, albeit with a longer development horizon, potentially 8-12 years for initial commercialization, opening access to a new therapeutic area.
• **Strategic Partnerships and Collaborations:** Immunocore's innovative ImmTAC® platform and clinical-stage assets make it an attractive partner for larger pharmaceutical companies seeking to expand their immunotherapy portfolios. Collaborations could provide non-dilutive funding, shared development costs, and access to broader commercialization capabilities, accelerating pipeline progression and market penetration. Such partnerships, potentially involving co-development or licensing agreements, could unlock significant value and accelerate the development of multiple candidates simultaneously, potentially impacting financial performance within the next 2-5 years.

What Opportunities Does IMCR Have?

• Expansion of KIMMTRAK's indications or geographic markets.
• Successful advancement and commercialization of multiple pipeline candidates in large markets (e.g., NSCLC, chronic HBV).
• Strategic partnerships and collaborations to accelerate development and market access.
• Leveraging the ImmTAC® platform for new therapeutic areas like autoimmune diseases.

What Threats Does IMCR Face?

• Clinical trial failures or delays for pipeline candidates.
• Intense competition from other immunotherapy developers and novel treatment modalities.
• Regulatory hurdles and potential market access challenges for new drugs.
• Patent expiry or intellectual property challenges for its core technology.

What Are IMCR's Competitive Advantages?

• Proprietary ImmTAC® (Immune mobilizing monoclonal TCRs Against Cancer) technology platform, enabling targeting of intracellular antigens.
• First-in-class approved product, KIMMTRAK, for unresectable or metastatic uveal melanoma, establishing market leadership in this niche.
• Extensive clinical and preclinical pipeline leveraging the same core technology, demonstrating broad applicability.
• Strong intellectual property portfolio protecting its TCR-based immunotherapies and development processes.

What Does IMCR Do?

Founded in 1999 and headquartered in Abingdon, United Kingdom, Immunocore Holdings plc has evolved into a commercial-stage biotechnology company dedicated to developing novel immunotherapies. The company's core focus lies in harnessing the power of T-cell receptors (TCRs) to target intracellular proteins, a strategy that differentiates its approach from conventional antibody-based therapies. This innovative platform allows Immunocore to address a broader range of diseases, including various cancers, infectious diseases, and autoimmune conditions. Immunocore's flagship product, KIMMTRAK (tebentafusp-tebn), has achieved commercialization for the treatment of adult patients with unresectable or metastatic uveal melanoma, a rare and aggressive form of eye cancer. This represents a significant milestone, validating the company's proprietary ImmTAC® (Immune mobilizing monoclonal TCRs Against Cancer) technology. The development of KIMMTRAK involved extensive clinical trials, demonstrating its efficacy in a patient population with limited treatment options. Beyond its approved product, Immunocore maintains a robust and diversified pipeline. In oncology, key programs include IMC-C103C, currently in a Phase I/II dose escalation trial targeting solid tumor cancers such as non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma. Another promising oncology candidate is IMC-F106C, also in a Phase I/II dose escalation trial for multiple solid tumor cancers, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. These programs aim to expand the application of Immunocore's TCR technology across a broader spectrum of oncology indications, potentially addressing significant unmet medical needs. The company's therapeutic scope extends beyond cancer into infectious diseases, with programs like IMC-I109V, which is in a Phase I/II clinical trial for chronic hepatitis B virus (HBV), a global health challenge. Additionally, IMC-M113V is in preclinical development for human immunosuppression virus (HIV), indicating a long-term commitment to addressing chronic viral infections. Immunocore is also exploring the application of its technology to autoimmune diseases, developing product candidates designed to provide precision-targeted immunosuppression. This broad pipeline strategy underscores Immunocore's ambition to leverage its unique TCR platform across multiple therapeutic areas, establishing a significant presence in the global biopharmaceutical landscape. The company employs 493 individuals, reflecting its operational scale and research intensity.

What Products and Services Does IMCR Offer?

• Develops immunotherapies using its proprietary T-cell receptor (TCR) technology.
• Focuses on treatments for cancer, infectious diseases, and autoimmune conditions.
• Offers KIMMTRAK (tebentafusp-tebn) for unresectable or metastatic uveal melanoma.
• Conducts Phase I/II trials for oncology candidates IMC-C103C and IMC-F106C for various solid tumors.
• Advances infectious disease programs, including IMC-I109V for chronic hepatitis B virus in clinical trials.
• Engages in preclinical development for IMC-M113V targeting human immunosuppression virus.
• Researches product candidates for precision-targeted immunosuppression in autoimmune diseases.
• Operates as a commercial-stage biotechnology company headquartered in the United Kingdom.

How Does IMCR Make Money?

• Generates revenue from the sales of its approved immunotherapy product, KIMMTRAK, for uveal melanoma.
• Pursues milestone payments and royalties from potential future licensing agreements or collaborations for its pipeline assets.
• Invests significantly in research and development to advance its proprietary ImmTAC® platform and expand its therapeutic pipeline.
• Aims to commercialize additional drug candidates across oncology, infectious, and autoimmune diseases upon successful clinical development and regulatory approval.

What Industry Does IMCR Operate In?

Immunocore Holdings plc operates within the highly innovative and competitive biotechnology industry, specifically focusing on immunotherapy development. The global immunotherapy market is experiencing significant growth, driven by advancements in understanding immune mechanisms and the increasing prevalence of cancer and chronic infectious diseases. Immunocore differentiates itself through its proprietary ImmTAC® platform, which utilizes soluble T-cell receptors to target intracellular antigens, a unique approach compared to traditional antibody-based therapies that primarily target cell surface proteins. This allows Immunocore to address a broader range of disease targets. The competitive landscape includes large pharmaceutical companies and other biotechnology firms developing various forms of immunotherapies, including checkpoint inhibitors, CAR-T cell therapies, and other T-cell engaging bispecifics. Immunocore's commercial success with KIMMTRAK for uveal melanoma positions it as a key player in niche oncology markets, while its pipeline aims to expand its footprint into larger oncology indications and infectious/autoimmune diseases, aligning with the broader trend towards precision medicine and targeted therapies.

Who Are IMCR's Key Customers?

• Oncology patients diagnosed with unresectable or metastatic uveal melanoma.
• Healthcare providers and oncologists who prescribe KIMMTRAK.
• Future patient populations suffering from various solid tumor cancers, chronic hepatitis B, human immunosuppression virus, and autoimmune diseases.
• Hospitals, clinics, and specialized treatment centers globally.

FY2026 estForward Outlook

Wall Street analysts project Immunocore Holdings plc revenue of about $447.4M for fiscal 2026, with EPS near $0.12. The estimate reflects 11 contributing analysts.

IMCR Valuation & Market Position

With a $1.73B market cap, Immunocore Holdings plc sits in the small-cap segment of the market. Relative to its peer group, IMCR's quantitative score of 65/100 is below the peer average of 82/100.

ROE -5%Key Financial Metrics

Return on equity for Immunocore Holdings plc stands at -4.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Immunocore Holdings plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.32 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Immunocore Holdings plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Abingdon, GB. The company is led by CEO Bahija Jallal. IMCR has traded publicly since 2021.

IMCR Financials

IMCR Latest News

IMCR Analyst Consensus

IMCR MoonshotScore

What Investors Ask About Immunocore Holdings plc (IMCR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources